{"name":"Taizhou EOC Pharma Co., Ltd.","slug":"taizhou-eoc-pharma-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"EOC202","genericName":"EOC202","slug":"eoc202","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"EOC202","genericName":"EOC202","slug":"eoc202","phase":"phase_2","mechanism":"EOC202 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxNTWV1V1kzTHhlRllWSVV5X2dKV1lwbEplaVo4VE5LNWVFRHpJcEw1c1Z6SjRuOWxRakZISHRRWFlrU0lndDl2VzVpdWllWG1mTXN5SkFZRmY1QXlibDJTLU9vT1ZnejFXRzlCUS1CTDcwWnNnaEFheW5QaUZveG5FYTNoeWxKQXpSclZ2alBUaTBaZFNnQmFPSDVzUDQ0bnBPWTZmV19fSWVaVTJzak1IOE82T25USjFwZ3MwenpjbGVobHdtSy1JZ1l5Sm1NNmY3Tm4xTDdYQUR0dHNnR1Z0OVB2Z0NuN0dTM0p0emVRb0RkLWFuNExTMmp2dHhaRkdzcHBqUXRPOUtLdTBkVmZDaDJ4dUpRc0k?oc=5","date":"2025-04-30","type":"pipeline","source":"globenewswire.com","summary":"Metastatic HR+/HER2- Breast Cancer Market—The Road Ahead - globenewswire.com","headline":"Metastatic HR+/HER2- Breast Cancer Market—The Road Ahead","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxOT3V0UTc3SUE5NDZKYmcxR292V2pYcVhMWjlfaGRfZlpqYTlQYzhRd3RoNXI3N3doZU5ReEVoZmI4RUlBYkM2VWJwNnFWc2xwajk0eWp4RWJvWnZVS1NrRlJuOHlVX1BxQmZPWXMwWFRKWjBpU240ajlrUzNpcWpwR05RMUtycGNUMHZmOHRMWEtNS1NxLUxmNXJxWnlPREhkbThuS0RSSU15cWM5ZUJUam0zd3ZhOGJVaTB3TDl2WTlBMHFKNzZ1NDFpaXNUYzM2LWgtcUl4VHNNbm8yWVc1SVZTT1ota2ZJb3RZVGphY0hOR2FsZ1R5MWs4NVk3MEVYd1dWMk8xSEIwRUZJ?oc=5","date":"2025-04-24","type":"pipeline","source":"PR Newswire","summary":"IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | DelveInsight - PR Newswire","headline":"IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | Del","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPR21PRG9kQ29fZjF6Q3FhU0VnWThCdVZlUzh4b1F6UE1WbHhWX25NOFMxNVhaTmVaQlFqN2M0dnYxb1h6Ujh1bXNFVk0xcE5JMlEyLXY5UEVRZUtGNkw4dG5ydEdpZm8tVlVRNjhMOERuU3k5ZV9EcmlSbkgtdmZvQTI0YUxnTERhUEgzUkFKM2RoTWlINGk4TGFZcV9XY2NsTFRmWTR1d04yMThzMEFCbUpkcV9LMTN1RlVGS0FBSG8tYXNvTElHMnUxd2FOOGo0MkhXNU9n?oc=5","date":"2025-03-13","type":"regulatory","source":"PR Newswire","summary":"VERZENIO's Market Potential Soars as Demand for CDK4/6 Inhibitors Grows | DelveInsight - PR Newswire","headline":"VERZENIO's Market Potential Soars as Demand for CDK4/6 Inhibitors Grows | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}